Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Strain EC, Harrison JA, Bigelow GE.

Clin Pharmacol Ther. 2011 Mar;89(3):443-9. doi: 10.1038/clpt.2010.352. Epub 2011 Jan 26.

2.

Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.

Webster L, Hjelmström P, Sumner M, Gunderson EW.

J Addict Dis. 2016 Oct-Dec;35(4):325-338. Epub 2016 Jun 7.

PMID:
27267785
3.

Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.

Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, Blasey C, Sigmon S, Beebe KL.

Addiction. 2013 Dec;108(12):2141-9. doi: 10.1111/add.12315. Epub 2013 Sep 18.

4.

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.

Am J Addict. 2004;13 Suppl 1:S42-66.

5.

Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.

Sullivan JG, Webster L.

Clin Ther. 2015 May 1;37(5):1064-75. doi: 10.1016/j.clinthera.2015.02.027. Epub 2015 Mar 29.

6.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
7.
8.

Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.

Gunderson EW, Hjelmström P, Sumner M; 006 Study Investigators.

Clin Ther. 2015 Oct 1;37(10):2244-55. doi: 10.1016/j.clinthera.2015.08.025. Epub 2015 Sep 26.

9.

Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.

Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.

PMID:
20450242
10.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
11.

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD.

Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x. Erratum in: Addiction. 2010 Jul;105(7):1332.

12.

Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Montesano F, Zaccone D, Battaglia E, Genco F, Mellace V.

Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.

PMID:
20450241
13.

A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.

Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.

Addiction. 2012 Jan;107(1):142-51. doi: 10.1111/j.1360-0443.2011.03577.x. Epub 2011 Oct 12.

PMID:
21749526
14.

Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.

Gunderson EW, Sumner M.

J Addict Med. 2016 Mar-Apr;10(2):124-30. doi: 10.1097/ADM.0000000000000201.

15.

Commercial factors override science in combination addiction drug trial.

Byrne A.

Clin Pharmacol Ther. 2011 Nov;90(5):649; author reply 650. doi: 10.1038/clpt.2011.166. Epub 2011 Sep 28. No abstract available.

PMID:
21956617
16.

Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR.

Drug Alcohol Depend. 2016 May 1;162:190-8. doi: 10.1016/j.drugalcdep.2016.03.005. Epub 2016 Mar 14.

18.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
19.

Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.

Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2006 Dec;189(3):297-306. Epub 2006 Sep 30.

PMID:
17013637
20.

Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Rosado J, Walsh SL, Bigelow GE, Strain EC.

Drug Alcohol Depend. 2007 Oct 8;90(2-3):261-9. Epub 2007 May 22.

Supplemental Content

Support Center